WO2023047348 - STABILIZED CORONA VIRUS SPIKE PROTEIN FUSION PROTEINS
National phase entry is expected:
Publication Number
WO/2023/047348
Publication Date
30.03.2023
International Application No.
PCT/IB2022/059015
International Filing Date
23.09.2022
Title **
[English]
STABILIZED CORONA VIRUS SPIKE PROTEIN FUSION PROTEINS
[French]
PROTÉINES DE FUSION DE PROTÉINE DE SPICULE DE CORONAVIRUS STABILISÉES
Applicants **
JANSSEN PHARMACEUTICALS, INC.
1125 Trenton-Harbourton Road
Titusville, New Jersey 08560, US
Inventors
LANGEDIJK, Johannes Petrus Maria
Archimedesweg 4-6
2333 CN Leiden, NL
RUTTEN, Lucy
Archimedesweg 4-6
2333 CN Leiden, NL
JURASZEK, Jaroslaw
Archimedesweg 4-6
2333 CN Leiden, NL
Priority Data
63/261,594
24.09.2021
US
21205007.4
27.10.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1730 | |
| EPO | Filing, Examination | 8272 | |
| Japan | Filing | 593 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 6835 |
Total: 18038 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to stabilized recombinant pre-fusion SARS CoV-2 S proteins, and fragments thereof, as well as nucleic acids molecules encoding the SARS CoV-2 S proteins or fragments thereof, and to uses thereof.[French]
La présente invention concerne des protéines S de SARS-CoV-2 de pré-fusion recombinantes stabilisées, et des fragments de celles-ci, ainsi que des molécules d'acides nucléiques codant pour les protéines S du SARS-CoV-2 ou des fragments de celles-ci, et leurs utilisations.